Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies
Paul Oster, Laurie Vaillant, Erika Riva, Brynn McMillan, Christina Begka, Caroline Truntzer, Corentin Richard, Marine M Leblond, Meriem Messaoudene, Elisavet Machremi, Emeric Limagne, Francois Ghiringhelli, Bertrand Routy, Gregory Verdeil, Dominique Velin, Paul Oster, Laurie Vaillant, Erika Riva, Brynn McMillan, Christina Begka, Caroline Truntzer, Corentin Richard, Marine M Leblond, Meriem Messaoudene, Elisavet Machremi, Emeric Limagne, Francois Ghiringhelli, Bertrand Routy, Gregory Verdeil, Dominique Velin
Abstract
Objective: In this study, we determined whether Helicobacter pylori (H. pylori) infection dampens the efficacy of cancer immunotherapies.
Design: Using mouse models, we evaluated whether immune checkpoint inhibitors or vaccine-based immunotherapies are effective in reducing tumour volumes of H. pylori-infected mice. In humans, we evaluated the correlation between H. pylori seropositivity and the efficacy of the programmed cell death protein 1 (PD-1) blockade therapy in patients with non-small-cell lung cancer (NSCLC).
Results: In mice engrafted with MC38 colon adenocarcinoma or B16-OVA melanoma cells, the tumour volumes of non-infected mice undergoing anticytotoxic T-lymphocyte-associated protein 4 and/or programmed death ligand 1 or anti-cancer vaccine treatments were significantly smaller than those of infected mice. We observed a decreased number and activation status of tumour-specific CD8+ T cells in the tumours of infected mice treated with cancer immunotherapies independent of the gut microbiome composition. Additionally, by performing an in vitro co-culture assay, we observed that dendritic cells of infected mice promote lower tumour-specific CD8+ T cell proliferation. We performed retrospective human clinical studies in two independent cohorts. In the Dijon cohort, H. pylori seropositivity was found to be associated with a decreased NSCLC patient survival on anti-PD-1 therapy. The survival median for H. pylori seropositive patients was 6.7 months compared with 15.4 months for seronegative patients (p=0.001). Additionally, in the Montreal cohort, H. pylori seropositivity was found to be associated with an apparent decrease of NSCLC patient progression-free survival on anti-PD-1 therapy.
Conclusion: Our study unveils for the first time that the stomach microbiota affects the response to cancer immunotherapies and that H. pylori serology would be a powerful tool to personalize cancer immunotherapy treatment.
Keywords: Helicobacter pylori; cancer; cancer immunobiology; immunotherapy.
Conflict of interest statement
Competing interests: FG received honoraria for oral communication from Lilly, Sanofi, Amgen, and is an advisory board of Merck Serono, Amgen and Sanofi. The remaining authors declare no conflicts of interest.
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Figures
References
- Gopalakrishnan V, Helmink BA, Spencer CN, et al. . The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell 2018;33:570–80. 10.1016/j.ccell.2018.03.015
- Vétizou M, Pitt JM, Daillère R, et al. . Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015;350:1079–84. 10.1126/science.aad1329
- Gopalakrishnan V, Spencer CN, Nezi L, et al. . Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018;359:97–103. 10.1126/science.aan4236
- Routy B, Le Chatelier E, Derosa L, et al. . Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018;359:91–7. 10.1126/science.aan3706
- Cheng WY, Wu C-Y, Yu J. The role of gut microbiota in cancer treatment: friend or foe? Gut 2020;69:1867–76. 10.1136/gutjnl-2020-321153
- Elkrief A, Derosa L, Kroemer G, et al. . The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? Ann Oncol 2019;30:1572–9. 10.1093/annonc/mdz206
- Roberti MP, Yonekura S, Duong CPM, et al. . Chemotherapy-Induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. Nat Med 2020;26:919–31. 10.1038/s41591-020-0882-8
- Moyat M, Velin D. Immune responses to Helicobacter pylori infection. World J Gastroenterol 2014;20:5583–93. 10.3748/wjg.v20.i19.5583
- Altobelli A, Bauer M, Velez K, et al. . Helicobacter pylori VacA Targets Myeloid Cells in the Gastric Lamina Propria To Promote Peripherally Induced Regulatory T-Cell Differentiation and Persistent Infection. mBio 2019;10:10:e00261–19. 10.1128/mBio.00261-19
- Ricci V, Giannouli M, Romano M, et al. . Helicobacter pylori gamma-glutamyl transpeptidase and its pathogenic role. World J Gastroenterol 2014;20:630–8. 10.3748/wjg.v20.i3.630
- Arnold IC, Zhang X, Artola-Boran M, et al. . BATF3-dependent dendritic cells drive both effector and regulatory T-cell responses in bacterially infected tissues. PLoS Pathog 2019;15:e1007866. 10.1371/journal.ppat.1007866
- Engler DB, Reuter S, van Wijck Y, et al. . Effective treatment of allergic airway inflammation with Helicobacter pylori immunomodulators requires BATF3-dependent dendritic cells and IL-10. Proc Natl Acad Sci U S A 2014;111:11810–5. 10.1073/pnas.1410579111
- Zhuang Y, Cheng P, Liu X-fei, et al. . A pro-inflammatory role for Th22 cells in Helicobacter pylori-associated gastritis. Gut 2015;64:1368–78. 10.1136/gutjnl-2014-307020
- Chen Y, Blaser MJ. Helicobacter pylori colonization is inversely associated with childhood asthma. J Infect Dis 2008;198:553–60. 10.1086/590158
- Sawalha AH, Schmid WR, Binder SR, et al. . Association between systemic lupus erythematosus and Helicobacter pylori seronegativity. J Rheumatol 2004;31:1546–50.
- Luther J, Dave M, Higgins PDR, et al. . Association between Helicobacter pylori infection and inflammatory bowel disease: a meta-analysis and systematic review of the literature. Inflamm Bowel Dis 2010;16:1077–84. 10.1002/ibd.21116
- Dellon ES, Peery AF, Shaheen NJ, et al. . Inverse association of esophageal eosinophilia with Helicobacter pylori based on analysis of a US pathology database. Gastroenterology 2011;141:1586–92. 10.1053/j.gastro.2011.06.081
- Oertli M, Noben M, Engler DB, et al. . Helicobacter pylori -glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance. Proc Natl Acad Sci U S A 2013;110:3047–52. 10.1073/pnas.1211248110
- Oertli M, Sundquist M, Hitzler I, et al. . DC-derived IL-18 drives Treg differentiation, murine Helicobacter pylori-specific immune tolerance, and asthma protection. J Clin Invest 2012;122:1082–96. 10.1172/JCI61029
- Arnold IC, Dehzad N, Reuter S, et al. . Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J Clin Invest 2011;121:3088–93. 10.1172/JCI45041
- Engler DB, Leonardi I, Hartung ML, et al. . Helicobacter pylori-specific protection against inflammatory bowel disease requires the NLRP3 inflammasome and IL-18. Inflamm Bowel Dis 2015;21:854–61. 10.1097/MIB.0000000000000318
- Callahan MK, Postow MA, Wolchok JD. Ctla-4 and PD-1 pathway blockade: combinations in the clinic. Front Oncol 2014;4:385. 10.3389/fonc.2014.00385
- Murray T, Fuertes Marraco SA, Baumgaertner P, et al. . Very late antigen-1 marks functional Tumor-Resident CD8 T cells and correlates with survival of melanoma patients. Front Immunol 2016;7:573. 10.3389/fimmu.2016.00573
- Arnold IC, Zigova Z, Holden M, et al. . Comparative whole genome sequence analysis of the carcinogenic bacterial model pathogen Helicobacter felis. Genome Biol Evol 2011;3:302–8. 10.1093/gbe/evr022
- Mager LF, Burkhard R, Pett N, et al. . Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 2020;369:1481–9. 10.1126/science.abc3421
- Kienesberger S, Cox LM, Livanos A, et al. . Gastric Helicobacter pylori infection affects local and distant microbial populations and host responses. Cell Rep 2016;14:1395–407. 10.1016/j.celrep.2016.01.017
- Chen C-C, Liou J-M, Lee Y-C, et al. . The interplay between Helicobacter pylori and gastrointestinal microbiota. Gut Microbes 2021;13:1909459–2228. 10.1080/19490976.2021.1909459
- Sivan A, Corrales L, Hubert N, et al. . Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015;350:1084–9. 10.1126/science.aac4255
- Wilson BE, Routy B, Nagrial A, et al. . The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies. Cancer Immunol Immunother 2020;69:343–54. 10.1007/s00262-019-02453-2
- Iida N, Dzutsev A, Stewart CA, et al. . Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013;342:967–70. 10.1126/science.1240527
- Uribe-Herranz M, Bittinger K, Rafail S, et al. . Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12. JCI Insight 2018;3. doi:10.1172/jci.insight.94952. [Epub ahead of print: 22 Feb 2018].
- van Wijck Y, de Kleijn S, John-Schuster G, et al. . Therapeutic Application of an Extract of Helicobacter pylori Ameliorates the Development of Allergic Airway Disease. J Immunol 2018;200:3027.2–8. 10.4049/jimmunol.1800260
- Fumet J-D, Richard C, Ledys F, et al. . Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. Br J Cancer 2018;119:950–60. 10.1038/s41416-018-0220-9
- Oertli M, Noben M, Engler DB, et al. . Helicobacter pylori γ-glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance. Proc Natl Acad Sci U S A 2013;110:3047–52. 10.1073/pnas.1211248110
- Koch KN, Hartung ML, Urban S, et al. . Helicobacter urease-induced activation of the TLR2/NLRP3/IL-18 axis protects against asthma. J Clin Invest 2015;125:3297–302. 10.1172/JCI79337
- Kalali B, Mejías-Luque R, Javaheri A, et al. . H. pylori virulence factors: influence on immune system and pathology. Mediators Inflamm 2014;2014:1–9. 10.1155/2014/426309
- Kyburz A, Urban S, Altobelli A, et al. . Helicobacter pylori and its secreted immunomodulator vacA protect against anaphylaxis in experimental models of food allergy. Clin Exp Allergy 2017;47:1331–41. 10.1111/cea.12996
- Al Nabhani Z, Dulauroy S, Marques R, et al. . A weaning reaction to microbiota is required for resistance to Immunopathologies in the adult. Immunity 2019;50:1276–88. 10.1016/j.immuni.2019.02.014
- Ivanov II, Atarashi K, Manel N, et al. . Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009;139:485–98. 10.1016/j.cell.2009.09.033
- Chen D, Wu J, Jin D, et al. . Fecal microbiota transplantation in cancer management: current status and perspectives. Int J Cancer 2019;145:2021–31. 10.1002/ijc.32003
- Baruch EN, Youngster I, Ben-Betzalel G, et al. . Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 2021;371:602–9. 10.1126/science.abb5920
- Davar D, Dzutsev AK, McCulloch JA, et al. . Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 2021;371:595–602. 10.1126/science.abf3363
- Velin D, Bachmann D, Bouzourene H, et al. . Mast cells are critical mediators of vaccine-induced Helicobacter clearance in the mouse model. Gastroenterology 2005;129:142–55. 10.1053/j.gastro.2005.04.010
- Velin D, Favre L, Bernasconi E, et al. . Interleukin-17 is a critical mediator of vaccine-induced reduction of Helicobacter infection in the mouse model. Gastroenterology 2009;136:2237–46. 10.1053/j.gastro.2009.02.077
- Begka C, Pattaroni C, Mooser C, et al. . Toll-Interacting protein regulates immune cell infiltration and promotes colitis-associated cancer. iScience 2020;23:100891. 10.1016/j.isci.2020.100891
- van Zanten SJOV, Kolesnikow T, Leung V, et al. . Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model. Antimicrob Agents Chemother 2003;47:2249–55. 10.1128/AAC.47.7.2249-2255.2003
- Yadava K, Pattaroni C, Sichelstiel AK, et al. . Microbiota promotes chronic pulmonary inflammation by enhancing IL-17A and autoantibodies. Am J Respir Crit Care Med 2016;193:975–87. 10.1164/rccm.201504-0779OC
- D'Amato A, Di Cesare Mannelli L, Lucarini E, et al. . Faecal microbiota transplant from aged donor mice affects spatial learning and memory via modulating hippocampal synaptic plasticity- and neurotransmission-related proteins in young recipients. Microbiome 2020;8:140. 10.1186/s40168-020-00914-w
- Moyat M, Bouzourene H, Ouyang W, et al. . IL-22-induced antimicrobial peptides are key determinants of mucosal vaccine-induced protection against H. pylori in mice. Mucosal Immunol 2017;10:271–81. 10.1038/mi.2016.38
- Trompette A, Gollwitzer ES, Pattaroni C, et al. . Dietary Fiber Confers Protection against Flu by Shaping Ly6c- Patrolling Monocyte Hematopoiesis and CD8+ T Cell Metabolism. Immunity 2018;48:992–1005. 10.1016/j.immuni.2018.04.022
Source: PubMed